RECEIVED CENTRAL FAX CENTER APR 2 3 2007

PATENT Attorney Docket No. 701319 DHHS Ref. No. E-200-1990/4-US-06

In re Application of:

Schlom et al.

Art Unit: 1642

Application No. 09/693,121

Examiner Yaen Christopher

Filed: October 20, 2000

•

GENERATION OF IMMUNE RESPONSE TO PROSTATE-

SPECIFIC ANTIGEN (PSA)

SUBSTITUTE POWER OF ATTORNEY UNDER 37 CFR 3.71

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

For:

The Government of the United States of America, represented by the Secretary, Department of Health and Human Services ("Assignee") is the assignee of the entire right, title, and interest in the above-identified U.S. patent application ("the application") as evidenced by the following: an Assignment from inventor Jeffrey Schlom to The Government of the United States of America, represented by the Secretary, Department of Health and Human Services, recorded in the U.S. Patent and Trademark Office on March 26, 2007, at Reel 019062, Frame No. 0739; an assignment from inventor Dennis Panicali to Therion Biologics Corporation, recorded in the U.S. Patent and Trademark Office on November 24, 1995, at Reel 007725, Frame No. 0856; a Security Agreement from Therion Biologics Corporation to H&Q Healthcare Investors, recorded in the U.S. Patent and Trademark Office on May 5, 1997, at Reel 008483, Frame No. 0463; a Release of Security Interest from Allan G. Carr to Therion Biologics Corporation, recorded in the U.S. Patent and Trademark Office on January 16, 1998, at Reel 008940, Frame No. 0525; a Security Interest from Therion Biologics Corporation to Allan G. Carr, recorded in the U.S. Patent and Trademark Office on June 22, 2001, at Reel 011923, Frame No. 0105; a Release of Security Agreement from Allan G. Carr to Therion Biologics Corporation, recorded in the U.S. Patent and Trademark Office on October 15, 2001, at Reel 012252, Frame No. 0709; an Assignment from Therion Biologics Corporation to The Government of the United States of America, represented by the Secretary, Department of Health and Human Services, recorded in the U.S. Patent and Trademark Office on March 15, 2007, at Reel 019019, Frame No. 0113.

In re Appln. of Schlom et al. Application No. 09/693,121

In accordance with 37 CFR 3.73(b), the undersigned certifies that the undersigned is authorized to act on behalf of the assignee, has reviewed all of the evidentiary documents accompanying or referred to in this Substitute Power of Attorney and, to the best of the undersigned's knowledge and belief, that title is in the Assignee.

The Assignee hereby revokes all previous powers of attorney and appoints the following attorneys and patent agents of the National Institutes of Health, Office of Technology Transfer, and of Leydig, Voit & Mayer, Ltd., who are identified with the following Customer Number, to prosecute and transact all business in the U.S. Patent and Trademark Office connected with the application, including but not limited to receiving all documents issued by the U.S. Patent and Trademark Office based thereon, filing continuation, continuation-in-part, and divisional applications based thereon, paying any and all fees, including maintenance fees for any resulting patent, filing for reissues and extensions of any resulting patent, and requesting reexamination of any resulting patent:

45733

The assignee further requests that correspondence concerning this application be directed to Leydig, Voit & Mayer, Ltd., as Customer Number:

45733

The assignee also requests that all telephone calls be directed to Leydig, Voit & Mayer, Ltd. at (312) 616-5600.

Respectfully submitted,

TRUMPLES LICENSIA SPACEMENT

NIH, or Programs # 55,013
NIH Office of Technology Transfer
6011 Executive Blvd., Suite 325

Rockville, MD 20852-3804

(301) <u>451-7334</u>

Date: 29 4464 2007